Bronchiectasis Care with BRINSUPRI: The First Approval in NCFB

Learning Theater 2
Supported by: Insmed

---

Program Description

Learn about BRINSUPRI™ (brensocatib), the first and only FDA-approved treatment specifically for non-cystic fibrosis bronchiectasis (NCFB), at Learning Theater 2 on Monday, October 20, at 12:15 PM CT. BRINSUPRI is indicated for the treatment of NCFB in adult and pediatric patients 12 years of age and older.¹

Over lunch, Professor James Chalmers, MBChB, PhD, will discuss an overview of bronchiectasis, the introduction to BRINSUPRI, and results from the largest clinical trial program for bronchiectasis (ASPEN and WILLOW studies).^1,2 This session will help you to identify and diagnose bronchiectasis, determine which patients are suitable for BRINSUPRI, and review results from the ASPEN and WILLOW studies.

Bronchiectasis is a chronic and progressive inflammatory lung disease. Chronic neutrophilic inflammation can lead to lung function decline and an increased risk of exacerbations. A new treatment option is available for patients with bronchiectasis: BRINSUPRI. BRINSUPRI targets a key driver of inflammation in bronchiectasis. This now-approved, once-daily treatment option may be able to help patients with NCFB.^1,3–7

In addition to attending the Learning Theater event, you can learn more about the efficacy and safety of BRINSUPRI by visiting booth #1816 during CHEST 2025. A variety of educational resources will be available, including interactive data presentations with clinical trial results, a hands-on display of the mechanism of action of BRINSUPRI, a real patient story, and information about the prescription process. Demonstrate your BRINSUPRI knowledge by playing the “Meet the Sunrise” game and see how your patients compare to participants in the ASPEN study with an interactive tool. Printed resources will be available for you to read and keep, and staff will be onsite to answer any questions you may have. You can also explore BRINSUPRIhcp.com for more information about the BRINSUPRI clinical profile, resources, and more. Insmed looks forward to seeing you at CHEST 2025.

References: 1. BRINSUPRI [package insert]. Bridgewater, NJ: Insmed Incorporated; 2025. 2. Chalmers JD, et al. ERJ Open Res. 2024;10(4):00151-2024. 3. Keir HR, Chalmers JD. Semin Respir Crit Care Med. 2021;42(4):499-512. 4. Chalmers JD, et al. Nat Rev Dis Primers. 2018;4(1):45. 5. Flume PA, et al. Lancet. 2018;392(10150):880-890. 6. Chalmers JD, et al. Am J Respir Crit Care Med. 2018;197(11):1410-1420. 7. Chalmers JD, et al. Am J Respir Crit Care Med. 2017;195(10):1384-1393.

PP-BRIN-US-00291

CHEST 2025 Disclaimer:

This presentation does not qualify for continuing medical education (CME). Attendance at this program is limited to healthcare professionals; guests or spouses cannot be accommodated. If you are a licensed US physician, any meals provided are reportable under Federal Open Payments. If you are a healthcare professional licensed in one or more states that place restrictions on meals provided by pharmaceutical companies, we may request that you do not consume any food or beverage provided by Insmed. VA/DoD personnel, please ensure you are meeting federal and site-specific expectations when attending programs.

IMPORTANT SAFETY INFORMATION 

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Live Attenuated Vaccines

It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

ADVERSE REACTIONS

The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions

Liver Function Test Elevations

In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.

Skin Cancers

In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia

In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information.

Speaker

Professor James D Chalmers, MBChB, PhD
University of Dundee, UK